Imaging Mass Cytometry May Identify Therapeutic Targets in ccRCC
July 13th 2023The tumor-immune evasion cell networks in clear cell renal cell carcinoma may be captured and classified using imaging mass cytometry, an orthogonal approach with the potential for increased cost-efffectiveness and accuracy compared with single-cell RNA sequencing.
Read More
Cilta-Cel Demonstrates Long-Term PFS, Safety in R/R Multiple Myeloma
June 11th 2023Administration of a single infusion of ciltacabtagene autoleucel prolonged progression-free survival, generated sustained responses, and continued to demonstrate a manageable safety profile in patients with relapsed/refractory multiple myeloma who were heavily pretreated, according to final results from the phase 1b/2 CARTITUDE-1 study.
Read More
Teclistamab Plus Talquetamab Demonstrates Encouraging ORR in Relapsed/Refractory Multiple Myeloma
June 10th 2023The combination of the BCMA- and GPRC5D-targeted bispecific antibodies, teclistamab and talquetamab, respectively, demonstrated encouraging overall response rates and was well tolerated in patients with relapsed or refractory multiple myeloma.
Read More
The addition of durvalumab to standard upfront therapy with chemotherapy and bevacizumab followed by maintenance bevacizumab, durvalumab, and olaparib led to a statistically significant improvement in progression-free survival compared with chemotherapy and bevacizumab alone in patients with newly diagnosed, advanced ovarian cancer without a BRCA1/2 mutation.
Read More
Nivolumab Plus Cabozantinib Shows Sustained Survival Advantage in Advanced RCC
February 19th 2023The combination of nivolumab and cabozantinib produced prolonged progression-free survival and higher response rates compared with sunitinib alone as frontline therapy in patients with advanced renal cell carcinoma, regardless of International Metastatic RCC Database Consortium risk status.
Read More
Neoadjuvant Tremelimumab/Durvalumab Elicits Responses in Gastric/GEJ Adenocarcinoma
January 19th 2023Neoadjuvant treatment with the combination of tremelimumab and durvalumab produced responses and was well tolerated in patients with mismatch repair–deficient and microsatellite instability–high, Epstein-Barr virus–negative gastric or gastroesophageal junction adenocarcinoma.
Read More
Teclistamab Triplet Shows Encouraging Responses and Safety in Relapsed/Refractory Multiple Myeloma
December 10th 2022Administration of teclistamab in combination with daratumumab and lenalidomide demonstrated promising overall response rates and tolerability in patients with relapsed/refractory multiple myeloma who had prior lenalidomide exposure, according to initial data from the phase 1b MajesTEC-2 trial.
Read More